Stable, clear, ophthalmic formulations and methods of use for an opthalmologically therapeutic effective amount of a TRPA1 antagonist, the formulation comprising buffer system, a viscosity enhancing agent, optionally a preservative, with an opthalmologically acceptable osmolarity and pH, all in an aqueous vehicle. These formulations are effective for treating ocular diseases or conditions caused by, or associated with, or accompanied by ocular pain and inflammatory processes, including, among others, dry eye N disease, uveitis, or any trauma caused by eye surgery or eye injury.
